by nms-sync | Oct 28, 2022 | News
Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 28 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS...
by nms-sync | Oct 26, 2022 | News
NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will...
by nms-sync | Oct 17, 2022 | News
Nerviano Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of...
by NMSGroup | Sep 21, 2022 | News
NERVIANO, 21 September 2022 Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement ...
by nms-sync | Aug 1, 2022 | News
Nerviano Medical Sciences S.r.l. (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today that it has expanded its presence in the US with the creation of a new US...
by nms-sync | Jul 19, 2022 | News
Nerviano Medical Sciences S.r.l., a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, recently announced that the first patient has been dosed in its Phase 1 clinical trial of NMS-812 in adult...
Recent Comments